According to TaskUs’ CEO and President Jaspar Weir, some of the biggest complaints in corporate culture are employee performance reviews and appraisals. There is a tremendous amount of time that goes into annual employee reviews, and yet more than half of executives (58%) believe that their current performance management approach drives neither employee engagement nor higher performance. Typically, companies use a rigid system of ratings and subjective evaluation criteria that is often not interpreted or acted on effectively due to lack of management training.
Realizing that there is more to success than just job performance, TaskUs has completely reimagined the employee review process through The Human Project.
See the full article here: Annual Reviews: Bringing Together Performance, Passion And Purpose (Forbes)
Tearsheet asked some of the top experts in online lending, including CrowdOut’s Alexander Schoenbaum, to describe what they feel are the top trends in their businesses.
“We believe that the biggest trend in online lending will be a search for diversity and differentiation,” said Schoenbaum. “With most investors now having found real estate and consumer lending platforms – and spreads compressing from an excess of capital and completion – they will look to alternative credit products that have not saturated the market…”
Read the full article: 17 experts chime in on the future of lending in 2019 and beyond (Tearsheet)
The actual design and construction of an oral film capable of effective therapeutic delivery can be challenging and requires the creation of new technologies. As a result of these innovations, buccal films are now a commercially viable dosage form that can solve many problems faced by the pharmaceutical industry, patients, and their caregivers, according to CURE Pharmaceutical’s CEO Rob Davidson and its COO Jessica Rousset.
Oral films will be able to replace daily injections, such as apomorphine shots taken by patients suffering from Parkinson’s disease. They can improve the bioavailability of drugs, such as cannabinoids, potentially lowering their dose and psychoactive side effects. When rapid symptom relief is needed, they can deliver a bolus effect. They are a convenient alternative to unpalatable liquids for children and hard-to-swallow pills for the elderly.
“CURE Pharmaceutical’s approach to buccal film development with CUREfilm leverages the inevitable salivary flush of a single layer film to create better drug-release profiles,” said Davidson and Rousset. “We design our products to combine the fast onset bolus effect of buccal delivery with the extended release of GI delivery to achieve an overall pulsatileor sustained-release profile. Indeed, with buccal delivery, blood levels can peak quickly, and a shorter half-life can mean the effect wears off rapidly.”
Read the full article: BUCCAL FILMS – Better Drug Release & Patient Experiences With Buccal Films (Drug Development & Delivery)
As 2019 approaches, “business as usual” is over. Social media has been weaponized to amplify anyone who opposes your actions or opinions. The status quo is under assault from every side. And it’s worth considering that every successful business is the status quo, by definition. Our very success now guarantees we’ll be watched, tested, probed and challenged.
That’s good, since we intend to win. But it means reputation management and crisis communication planning is not just smart, but critical to a company’s very existence. We need to be prepared to respond to issues from customers, shareholders, investors, employees and the media that would otherwise take us by surprise.
The new awareness is beyond dispute. According to consulting firm Mercer, “boards are now holding executives to higher standards, looking not just at how they treat people but also how they talk to and about them.” The Wall Street Journal reported that a group of venture capitalists is pushing a standard clawback clause proposal. The clause would make it easier for big investors to extract fines from companies embattled by controversy.
A company’s reputation is its bottom line. If your company’s reputation takes a hit on social media, your very existence as a company is in mortal peril.
Hundreds of individuals and companies have been destroyed or damaged due to negative brand reputation. Over 700 high-profile executives and employees across fields and industries have been called out by the #MeToo movement in the past year. By June, 190 of those accused were fired or left their jobs. Another 122 have been put on leave, suspended or are facing investigations since December 2016.
A study from Stanford showed that the fallout from bad behavior displayed by chief executives was long-lasting. The study looked at 38 incidents, which generated an average of 250 news stories each with media attention lasting almost five years. Shares suffered and, in a third of cases, firms faced further damage, including loss of major clients, federal investigations, shareholder lawsuits or proxy battles.
Our clients are on the front line of these battles and are well prepared to answer questions about their values and how they live by them because they’ve thought through their vulnerabilities and addressed weaknesses.
We use the following reputation risk management assessment tool to identify areas of vulnerabilities and help companies develop a C-Suite level response plan that is ready to communicate to every stakeholder.
We are our reputations, in business and in life. Good risk management lets us sleep well, and not wake up to bad news.
The four questions to ask before choosing a financial advisor, according to Lido Advisors’ Greg Kushner
As the senior managing director of a financial advisory firm, Lido Advisors’ Greg Kushner knows there’s no such thing as free financial advice. Smart investors ask questions, especially about how their advisor makes money. The Council of Economic Advisers under President Obama estimated Americans lose a whopping $17 billion a year as a result of overpaying on investment products that they buy based on conflicted advice.
Kushner says there are four questions to ask before choosing a financial advisor.
Read the full article: Four Of The Most Important Questions To Ask Before Choosing A Financial Advisor (Forbes)
Scientists from USC Marshall conducted a study to see what kind of effect a gadget’s color had on its long-term likability. And the results? In short, don’t be scared; skip the black and silver and go with the hue or shade that really speaks to you.
In their experiment, Eva C. Buechel and Claudia Townsend separated products into two categories: high-arousal devices (like those with intense colors or complex patterns) and low-arousal products designed with less stimulating colors like beige, black, or silver. From there, they performed a series of tests that involved asking participants to evaluate each product on things like predicted likability or irritation, and then again after participants had gotten a chance to actually use each product over varying periods of time.
Read the full article: Stop Waffling and Get That Brightly Colored Gadget—Science Suggests You’ll Like It More (Gizmodo)
CompoSecure, L.L.C., a pioneer and global leader in the design and manufacturing of premium financial cards, today announced that it has produced more than one million dual interface (EMV chip & contactless) metal cards. Style and innovation have come together to make these “must have” cards in the discerning consumer’s wallet. The global adoption of contactless payment cards is demonstrated in a new study by A. T. Kearney, which also points to future growth for this technology, especially in the U.S.
“This milestone secures CompoSecure’s leadership position as the number one producer of premium payment cards,” said Jon Wilk, CEO of CompoSecure. “Integrating the contactless technology into these next generation metal cards is extremely challenging. Only CompoSecure has cracked the code on supporting financial institution clients in their large-scale program launches that include metal cards. The global push for contactless cards by all of the major payment brands made this more important than ever.”
Read the full release: CompoSecure Manufactures One Million Dual Interface Premium Cards (BusinessWire)
The FM/a Test, a clinical diagnostic blood test which is performed by Los Angeles-based EpicGenetics, has been approved for use by the U.S. Food and Drug Administration (FDA). And now, EpicGenetics and Massachusetts General Hospital (MGH) are launching a Phase II clinical trial to test a tuberculosis vaccine, BCG, as a potential treatment for fibromyalgia.
The structure of the clinical trial is to enroll 300 patients who test positive for fibromyalgia with the FM/a Test. They will be split into two groups, one receiving the vaccine, the other receiving a placebo.
“Currently,” says Bruce Gillis, CEO of EpicGenetics, “the only objective way to get fibromyalgia confirmed is by having the test. We’re in the process of contacting the people who had the test and seeing if they want to participate. We’re encouraging other people who want to potentially volunteer to also get the test, so we can do this. The expectation is that if the results are as good as we hope, potentially in as little as six months, we will have further opportunity to expand the treatment to many, many more people as we collect the data. We don’t expect significant side effects and we expect fairly rapid responses to the BCG by the people who participate in the trial who receive it.”
Read the full article: EpicGenetics and Massachusetts General Hospital to Launch Fibromyalgia Clinical Trial (BioSpace)
CURE Pharmaceutical has signed a deal with Canopy Growth Corp (TSX:WEED, NYSE:CGC), where Canopy will have an exclusive license to CURE’s patented, multi-layer oral thin film technology for use with cannabis extracts and biosynthetic cannabinoids.
Jessica Rousset, COO for CURE Pharmaceutical, says the licence agreement allows CURE to accelerate and expand the impact of its technology by joining forces with Canopy, which has broad market access and resources to bring a product to market.
See coverage below:
CURE Pharmaceutical joins forces with Canopy Growth in exclusive partnership (Proactive Investors)
CURE Pharmaceutical Expands Distribution of CUREfilm Technology With First Licensing Agreement (Drug Development and Delivery)
Canopy Growth Corp. Scores Huge Pharma Deal (Motley Fool)
Private lending syndication platform CrowdOut Capital announced on Wednesday the completion of a multi-million dollar term loan to Shale Support, a provider of frac sand and logistical solutions to the oil and gas proppant market.
According to CrowdOut, the loan will support the acquisition of two sand mines, spanning over 1,000 acres that contain more than 100 million tons of recoverable high-grade frac sand, which are located near the prolific shale plays in the southeastern U.S., and finance capital expenditures to increase production capacity at the sand mines.
Read the full article: CrowdOut Provides Multi-Million Dollar Term Loan to Shale Support (CrowdFund Insider)